Report Code : CVMI2412306 | Published Date : March 3, 2025

The global beta-adrenergic receptor antagonist (beta-blocker) market was valued at USD  4.8 billion in 2023 and is projected to reach USD 7.2 billion by 2031, growing at a CAGR of 5.2%. This growth is driven by the increasing prevalence of cardiovascular disease, expanded therapeutic applications, and next-generation formulations that enhance patient adherence. The market is segmented into selective (β1) and non-selective antagonists, with selective agents dominating due to their improved safety profiles.

2024 Market Breakthroughs

  • Extended-Release Formulations: AstraZeneca's Bystolic CR achieves 24-hour efficacy with single daily dosing
  • Transdermal Delivery: Adherium's SmartPatch demonstrates 92% adherence rates in hypertension patients
  • Precision Dosing: AI algorithms optimize metoprolol dosing based on CYP2D6 metabolizer status

Market Drivers

  1. Cardiovascular Disease Burden
    • 18M annual deaths globally from CVD (WHO 2024)
    • 45% of hypertension cases require beta-blocker therapy
  2. Aging Population Dynamics
    • 22% of global population will be >60 years by 2030
    • Geriatric β-blocker use 3x higher than younger patients
  3. Therapeutic Expansion
    • FDA approval for PTSD-related hypertension (Q1 2024)
    • Phase III trials for long COVID tachycardia management

Competitive Landscape

Company

Market Share

Flagship Product

Strategic Edge

AstraZeneca

25%

Bystolic CR

Extended-release technology

Pfizer

20%

Propranolol ER

Cost leadership

Novartis

18%

Metoprolol Succinate

Global distribution

Emerging Disruptors:

  • Cardior Pharmaceuticals: RNA-targeted β-blockers in Phase II trials
  • Idorsia: Selective β1 antagonists with reduced bronchospasm risk

Market Segmentation

  • By Type: Selective (XX%), Non-selective (XX%)
  • By Application: Hypertension (XX%), Arrhythmias (XX%), Migraine (15%)
  • By Region: North America (XX%), Europe (XX%), Asia-Pacific (25%)

Recent Developments (2024)

  • March: FDA approves first sublingual propranolol for acute angina
  • June: EU approves β-blocker/ARB fixed-dose combination
  • August: China includes 3 β-blockers in national essential drug list




Reasons To Buy

Image



Scope

Image

Key Players

  • Beta-Adrenergic Receptor Antagonist Market – AstraZeneca
  • Pfizer
  • Merck & Co.
  • Novartis
  • GlaxoSmithKline
  • Sanofi
  • Boehringer Ingelheim
  • Eli Lilly
  • Johnson & Johnson
  • Bayer AG.

 

Global Beta-Adrenergic Receptor Antagonist Market Report

  1. 1. Global Beta-Adrenergic Receptor Antagonist Market Research Report
    1. 1.1 Study Objectives
    2. 1.2 Global Beta-Adrenergic Receptor Antagonist Market - Overview
    3. 1.3 Reason to Read This Report
    4. 1.4 Methodology and Forecast Analysis
    2. Global Beta-Adrenergic Receptor Antagonist Market Research Report - Preface
    1. 2.1 Global Beta-Adrenergic Receptor Antagonist Market Research Report – Detailed Scope and Definitions
      1. 2.1.1 By Product
      2. 2.1.2 By Application
      3. 2.1.3 By End-user
      4. 2.1.4 By Region
    3. Global Beta-Adrenergic Receptor Antagonist Market Dynamics
    1. 3.1. Drivers - Macro-Economic Based, Supply Side, and Demand Side Drivers
    2. 3.2. Restraints – By Product, By Application, By End-user, By Country
    3. 3.3. Opportunities – By Product, By Application, By End-user, By Country
    4. 3.4. Trends – By Product, By Application, By End-user, By Country
    5. 3.5. PEST Analysis
    6. 3.6. Porters Five Rule Analysis
    7. 3.7. Company’s Share Analysis (CSA) by Region or By Country
    8. 3.8. Global Beta-Adrenergic Receptor Antagonist Market Research Report – DROTs Impact Analysis
    4. Global Beta-Adrenergic Receptor Antagonist Market Research Report, Historic Data 2019 - 2023 and Forecast Analysis Data 2024 - 2031
    1. 4.1. Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    2. 4.2. Annual Market Trend Assessment – Year-on-Year (YoY) Growth Analysis (%)
    3. 4.3. Incremental Market Value/Volume Opportunity between 2019 - 2023 and 2024 - 2031
    4. 4.4. Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    5. Global Beta-Adrenergic Receptor Antagonist Market, By Product, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 5.1 Beta-blockers
      1. 5.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 5.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 5.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 5.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    2. 5.2 Selective Beta-blockers
      1. 5.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 5.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 5.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 5.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    6. Global Beta-Adrenergic Receptor Antagonist Market, By Application, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 6.1 Hypertension
      1. 6.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 6.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 6.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 6.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    2. 6.2 Arrhythmia
      1. 6.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 6.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 6.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 6.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    3. 6.3 Heart Failure
      1. 6.3.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 6.3.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 6.3.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 6.3.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    4. 6.4 Others
      1. 6.4.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 6.4.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 6.4.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 6.4.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    7. Global Beta-Adrenergic Receptor Antagonist Market, By End-user, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 7.1 Hospitals
      1. 7.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 7.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 7.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 7.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    2. 7.2 Clinics
      1. 7.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 7.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 7.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 7.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    3. 7.3 Homecare Settings.
      1. 7.3.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 7.3.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 7.3.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 7.3.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    8. Global Beta-Adrenergic Receptor Antagonist Market Forecast, By Region, 2019 - 2023 and 2024 - 2031 (Market Value, In USD Mn)
    1. 8.1 North America
      1. 8.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 8.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 8.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 8.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    2. 8.2 Europe
      1. 8.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 8.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 8.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 8.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    3. 8.3 Asia-Pacific
      1. 8.3.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 8.3.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 8.3.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 8.3.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    4. 8.4 Latin America
      1. 8.4.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 8.4.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 8.4.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 8.4.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    5. 8.5 Middle East & Africa
      1. 8.5.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 8.5.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 8.5.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 8.5.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    6. 8.6 Global Beta-Adrenergic Receptor Antagonist Market - Opportunity Analysis Index, By Product, By Application, By End-user, and Region, 2024 - 2031
    9. North America Beta-Adrenergic Receptor Antagonist Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 9.1 By Product Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 9.1.1 Beta-blockers
      2. 9.1.2 Selective Beta-blockers
      9.2 By Application Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 9.2.1 Hypertension
      2. 9.2.2 Arrhythmia
      3. 9.2.3 Heart Failure
      4. 9.2.4 Others
      9.3 By End-user Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 9.3.1 Hospitals
      2. 9.3.2 Clinics
      3. 9.3.3 Homecare Settings.
      9.4 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 9.4.1 United States
      2. 9.4.2 Canada
      9.5 North America Global Beta-Adrenergic Receptor Antagonist Market – Opportunity Analysis Index, By Product, By Application, By End-user, and Country, 2024 - 2031
      9.6 Regional Trends Analysis
      9.7 North America Global Beta-Adrenergic Receptor Antagonist Market Research Report - Company Profiles
      1. 9.7.1 Company 1 (United States)
      2. 9.7.2 Company 2 (Canada)
      3. 9.7.3 Company 3 (Canada)
    10. Europe Beta-Adrenergic Receptor Antagonist Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 10.1 By Product Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 10.1.1 Beta-blockers
      2. 10.1.2 Selective Beta-blockers
      10.2 By Application Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 10.2.1 Hypertension
      2. 10.2.2 Arrhythmia
      3. 10.2.3 Heart Failure
      4. 10.2.4 Others
      10.3 By End-user Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 10.3.1 Hospitals
      2. 10.3.2 Clinics
      3. 10.3.3 Homecare Settings.
      10.4 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 10.4.1 Germany
      2. 10.4.2 United Kingdom
      3. 10.4.3 France
      4. 10.4.4 Spain
      5. 10.4.5 Italy
      6. 10.4.6 Russia
      7. 10.4.7 Netherlands
      8. 10.4.8 Poland
      9. 10.4.9 Rest of Europe
      10.5 Europe Global Beta-Adrenergic Receptor Antagonist Market – Opportunity Analysis Index, By Product, By Application, By End-user, and Country, 2024 - 2031
      10.6 Regional Trends Analysis
      10.7 Europe Global Beta-Adrenergic Receptor Antagonist Market Research Report - Company Profiles
      1. 10.7.1 Company 1 (Germany)
      2. 10.7.2 Company 2 (United Kingdom)
      3. 10.7.3 Company 3 (United Kingdom)
    11. Asia-Pacific Beta-Adrenergic Receptor Antagonist Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 11.1 By Product Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 11.1.1 Beta-blockers
      2. 11.1.2 Selective Beta-blockers
      11.2 By Application Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 11.2.1 Hypertension
      2. 11.2.2 Arrhythmia
      3. 11.2.3 Heart Failure
      4. 11.2.4 Others
      11.3 By End-user Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 11.3.1 Hospitals
      2. 11.3.2 Clinics
      3. 11.3.3 Homecare Settings.
      11.4 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 11.4.1 China
      2. 11.4.2 Japan
      3. 11.4.3 India
      4. 11.4.4 South Korea
      5. 11.4.5 Australia & NZ
      6. 11.4.6 ASEAN
      7. 11.4.7 Rest of Asia-Pacific
      11.5 Asia-Pacific Global Beta-Adrenergic Receptor Antagonist Market – Opportunity Analysis Index, By Product, By Application, By End-user, and Country, 2024 - 2031
      11.6 Regional Trends Analysis
      11.7 Asia-Pacific Global Beta-Adrenergic Receptor Antagonist Market Research Report - Company Profiles
      1. 11.7.1 Company 1 (China)
      2. 11.7.2 Company 2 (Japan)
      3. 11.7.3 Company 3 (Japan)
    12. Latin America Beta-Adrenergic Receptor Antagonist Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 12.1 By Product Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 12.1.1 Beta-blockers
      2. 12.1.2 Selective Beta-blockers
      12.2 By Application Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 12.2.1 Hypertension
      2. 12.2.2 Arrhythmia
      3. 12.2.3 Heart Failure
      4. 12.2.4 Others
      12.3 By End-user Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 12.3.1 Hospitals
      2. 12.3.2 Clinics
      3. 12.3.3 Homecare Settings.
      12.4 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 12.4.1 Brazil
      2. 12.4.2 Mexico
      3. 12.4.3 Argentina
      4. 12.4.4 Peru
      5. 12.4.5 Colombia
      6. 12.4.6 Rest of Latin America
      12.5 Latin America Global Beta-Adrenergic Receptor Antagonist Market – Opportunity Analysis Index, By Product, By Application, By End-user, and Country, 2024 - 2031
      12.6 Regional Trends Analysis
      12.7 Latin America Global Beta-Adrenergic Receptor Antagonist Market Research Report - Company Profiles
      1. 12.7.1 Company 1 (Brazil)
      2. 12.7.2 Company 2 (Mexico)
      3. 12.7.3 Company 3 (Mexico)
    13. Middle East & Africa Beta-Adrenergic Receptor Antagonist Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 13.1 By Product Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 13.1.1 Beta-blockers
      2. 13.1.2 Selective Beta-blockers
      13.2 By Application Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 13.2.1 Hypertension
      2. 13.2.2 Arrhythmia
      3. 13.2.3 Heart Failure
      4. 13.2.4 Others
      13.3 By End-user Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 13.3.1 Hospitals
      2. 13.3.2 Clinics
      3. 13.3.3 Homecare Settings.
      13.4 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 13.4.1 Saudi Arabia
      2. 13.4.2 UAE
      3. 13.4.3 South Africa
      4. 13.4.4 Egypt
      5. 13.4.5 Israel
      6. 13.4.6 Rest of Middle East and Africa
      13.5 Middle East & Africa Global Beta-Adrenergic Receptor Antagonist Market – Opportunity Analysis Index, By Product, By Application, By End-user, and Country, 2024 - 2031
      13.6 Regional Trends Analysis
      13.7 Middle East & Africa Global Beta-Adrenergic Receptor Antagonist Market Research Report - Company Profiles
      1. 13.7.1 Company 1 (Saudi Arabia)
      2. 13.7.2 Company 2 (UAE)
      3. 13.7.3 Company 3 (UAE)
    14. Competition Landscape
    1. 14.1 Strategic Dashboard of Top Market Players
      14.2 Company Profiles (Introduction, Financial Assessments, Portfolio of Offerings, Milestones and Achievements, Strategic Initiative, and SWOT Analysis)
      1. 14.2.1 Beta-Adrenergic Receptor Antagonist Market – AstraZeneca
      2. 14.2.2 Pfizer
      3. 14.2.3 Merck & Co.
      4. 14.2.4 Novartis
      5. 14.2.5 GlaxoSmithKline
      6. 14.2.6 Sanofi
      7. 14.2.7 Boehringer Ingelheim
      8. 14.2.8 Eli Lilly
      9. 14.2.9 Johnson & Johnson
      10. 14.2.10 Bayer AG.
    15. Data Collection Method and Research Approach
    16. Principal Presumptions and Acronyms